Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study will enroll a total of 16 patients with advanced pancreatic cancer at Cedars-Sinai
Medical Center. All subjects will receive combination therapy of gemcitabine, nab-paclitaxel,
and L-glutamine. The study investigates what the appropriate dosage of L-glutamine is so that
there is the lowest risk of side effects, and whether the supplement will make standard
chemotherapy of gemcitabine and nab-paclitaxel more effective in treating advanced pancreatic
cancer.